Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37981564)

  • 1. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
    Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma.
    Ray MD; Kanters S; Beygi S; Best T; Wulff J; Limbrick-Oldfield E; Patel AR; Oluwole OO
    Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38901633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
    Oluwole OO; Ray MD; Zur RM; Ferrufino CP; Doble B; Patel AR; Bilir SP
    Front Immunol; 2024; 15():1393939. PubMed ID: 38855109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
    Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
    Matasar M; Sanchez Alvarez J; Parisé H; Zuk E; Di Maio D; Shapouri S; Kim E; Lin SW
    J Med Econ; 2024; 27(1):766-776. PubMed ID: 38712895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
    Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
    Julia E; Salles G
    Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
    Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
    Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
    Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
    Casulo C; Larson MC; Lunde JJ; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P; Cohen JB; Kahl BS; Burack WR; Koff JL; Mun Y; Masaquel A; Wu M; Wei MC; Shewade A; Li J; Cerhan J; Flowers CR; Link BK; Maurer MJ
    Lancet Haematol; 2022 Apr; 9(4):e289-e300. PubMed ID: 35358443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining the management of relapsed or refractory follicular lymphoma.
    Pagel JM; Burke JM; Leslie LA
    Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
    Mondello P; Ansell SM
    Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
    Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
    Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P; Cohen JB; Kahl BS; Burack WR; Koff JL; Mun Y; Masaquel A; Wu M; Wei MC; Shewade A; Li J; Cerhan JR; Link BK; Flowers CR
    Haematologica; 2023 Nov; ():. PubMed ID: 38031804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes.
    Proudman DG; Gupta D; Nellesen D; Yang J; Kamp BA; Mamlouk K; Cheson BD
    Oncotarget; 2022; 13():677-683. PubMed ID: 35574216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.